Overview

Apotransferrin in Atransferrinemia

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein transferrin. No regular treatment is available for these patients. The objective of this study is to investigate the pharmacokinetics, efficacy and safety of Apotransferrin replacement therapy in atransferrinemia patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sanquin
Sanquin Plasma Products BV